Cara Therapeutics, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Cara Therapeutics, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2018 to Q2 2024.
  • Cara Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending June 30, 2024 was $991K, a 85.7% decline year-over-year.
  • Cara Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending June 30, 2024 was $11M, a 59.5% decline year-over-year.
  • Cara Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $21M, a 49.9% decline from 2022.
  • Cara Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $41.9M, a 81.8% increase from 2021.
  • Cara Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $23M, a 83% decline from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $11M $991K -$5.94M -85.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $16.9M $2.14M -$4.03M -65.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $21M $3M -$257K -7.88% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $21.2M $4.87M -$5.95M -55% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $27.2M $6.93M -$16.1M -69.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $43.2M $6.17M +$1.38M +28.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $41.9M $3.26M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $10.8M -$9.46M -46.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $23M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $4.79M +$2.86M +148% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q3 2021 $20.3M +$11M +119% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q1 2021 $129M $1.94M -$6.16M -76.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $135M $112M +$108M +2385% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 $27.5M $9.27M +$3.48M +60.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $24M $5.63M +$426K +8.18% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $23.6M $8.09M +$3.71M +84.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $19.9M $4.51M -$1.02M -18.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $20.9M $5.79M +$723K +14.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 $20.2M $5.21M +$2.33M +81.2% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 $17.9M $4.38M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 $5.53M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $5.06M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 $2.87M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.